



#4

EXPRESS MAIL NO.: EL 477 032 589 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Kroczek

Application No.: 09/972,524

Group Art Unit: 1644

Filed: October 4, 2001

Examiner: To be assigned

For: METHODS FOR TREATMENT OF
ASTHMATIC DISORDERS

Attorney Docket No.: 7853-240

COPY OF PAPERS
ORIGINALLY FILED**SECOND PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with Rule 115 of the Rules of Practice, please enter the amendments made herein and consider the following remarks. Applicant submits herewith (a) a Response to the Notice to File Corrected Application Papers - Filing Date Granted ("the Notice"), together with a copy of the Notice; (b) a Substitute Specification in compliance with 37 C.F.R. § 1.52; and (c) a Statement Under 37 C.F.R. § 1.125. Also submitted herewith as Exhibit A is a copy of page 25 of the specification following entry of the amendments made herein.

It is estimated that no additional fee is necessary for filing this amendment. In the event an additional fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

IN THE SPECIFICATION

Please amend the specification, as follows:

On a new page 25 following page 24 of the substitute specification submitted herewith, please insert the following abstract heading and abstract:

Abstract of the Disclosure

The present invention relates to methods and compositions for the prevention and treatment and prevention of immune system disorders, including cancer, AIDS, asthmatic

disorders, autoimmune diseases, organ transplant rejection and chronic viral diseases such as HCV or HBV infections. The therapeutic methods of the invention comprise administering molecules that modulate the activity of 8F4, thereby modulating costimulation of T cells. The present invention further provides monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce said monoclonal antibodies. Pharmaceutical compositions comprising molecules that modulate the activity of 8F4 are also provided.

REMARKS

Pursuant to the Notice to File Corrected Application Papers - Filing Date Granted mailed November 20, 2001 in connection with the above identified application, Applicant has amended the specification by providing an abstract in compliance with 37 C.F.R. § 1.72(b). A copy of page 25 of the specification following entry of the Abstract submitted herewith is attached hereto as Exhibit A. Support for the Abstract can be found in the specification as originally filed, for example at page 1, lines 3-30. Accordingly, the amendments to the specification do not introduce new matter as defined in 35 U.S.C. § 132.

Entry of the amendments and consideration of the remarks made herein is respectfully requested.

Respectfully submitted,

Date January 22, 2002

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By:

Muna Abu-Shaar
Muna Abu-Shaar
Limited Recognition Under 37 C.F.R. § 10.9(b)
Copy of Certificate Enclosed

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures